Pharmacokinetics of progesterone a few other countries under the brand name Progestasert. It was marketed between 1976 and 2001. The IUD was never widely used due to a relatively high contraceptive failure rate of 2.9% and the requirement of annual replacement. It contained 38 mg progesterone and released 65 μg progesterone into the uterus per day (adding up to about 35 mg after one year). For comparison, a woman's body produces on average about 25 mg progesterone per day during the luteal phase. While effective as a form of contraception and for decreasing menstrual bleeding and discomfort, long-lived IUDs can fundamentally only deliver
Menstrual synchrony of the thawed axillary pad under their noses daily. The researchers concluded that odorless compounds collected from women during the late follicular phase of their menstrual cycles triggered hormonal events that shortened the menstrual cycles of the recipient women, and that odorless compounds collected from women during the time of ovulation triggered a hormonal event in the recipient women that lengthened their menstrual cycles. Stern and McClintock concluded that these findings "proved the existence of human pheromones" as well as illustrated manipulation of the human menstrual cycle. Researchers pointed out several flaws in their study. Whitten's main critiques was with